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The intestinal epithelium forms a unique interface for interactions between the body and food 
components. It allows selective passage of nutrients, while offering protection against harmful 
substances. Under physiological conditions, the epithelium maintains a peaceful relationship with the 
extremely large community of commensal bacteria that live in the intestine and influence our health. 1
The intrinsically dynamic epithelium with its ability to respond to luminal stimuli, provides ample 
possibilities to modulate intestinal physiology by nutrition and microbiota. 
Cholesterol is of vital importance for vertebrate cell membrane structure and function. 2 Metabolites of 
cholesterol, such as bile salts (BS), steroid hormones and oxysterols, fulfill important biological functions. 3
Hypercholesterolemia however represents a major risk factor for cardiovascular disease. 4,5 Cholesterol 
homeostasis is tightly regulated by its intestinal absorption, fecal excretion and de novo synthesis. 6 
Classically, fecal cholesterol excretion was believed to be primarily driven by cholesterol secreted via 
the hepatobiliary pathway. 7 However, it has very recently become apparent that direct secretion of 
cholesterol from the blood compartment to the intestine, the process now adopted “TransIntestinal 
Cholesterol Excretion” (TICE), plays a major role in fecal cholesterol disposal. 6,8 Reduction of cholesterol 
absorption and induction of TICE represent attractive targets to facilitate cholesterol disposal. Ideally, 
inhibition of cholesterol absorption and/or induction of TICE would be facilitated by simple dietary 
intervention. 
BS are important for absorption of cholesterol, fat and fat-soluble vitamins. On the other hand, elimination 
of excess cholesterol from the body is partly facilitated by breakdown of cholesterol to BS in the liver and 
their subsequent fecal excretion. 9
In this theses we assessed, in a quantitative manner, intestinal function with respect to its capacity to 
digest and absorb lipids (dietary fats, cholesterol and BS), and its capacity to secrete cholesterol under 
varying intestinal conditions. 
In this general introduction, first of all a short overview of BS homeostasis [1] and dietary lipid (dietary fat 
and cholesterol) absorption [2] will be provided. Subsequently, the introduction will cover cholesterol 
homeostasis including the transport of cholesterol through plasma [3], the characteristics, analytical 
possibilities and (pharmacological) inhibition of cholesterol synthesis [4] and absorption [5], and finally 
pathways of cholesterol excretion [6]. 
1. Bile salt homeostasis
Under physiological pH (6-8) biliary and intestinal bile acids are present in the form of sodium salts 10 and 
will therefore be referred to as BS. BS are amphiphatic molecules, which are produced by the liver from 
cholesterol. BS stimulate bile flow and biliary phospholipid (PL) secretion, regulate their own synthesis, 
and are indispensable for efficient lipid absorption (including dietary fats, cholesterol and fat-soluble 
vitamins A,D,E and K). Chenodeoxycholate (CDC) and cholate are the major primary (produced by the 
liver) BS. The rodent liver converts the majority of CDC to more hydrophilic α- and β-muricholic acid (α-/ 
β-MC). 11 Intrinsically, rodents show a more hydrophilic BS pool compared with humans. 12
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Nearly all BS are conjugated by liver peroxisomes, mainly with taurine in rodents and glycine in humans. 
12,13 The liver secretes these BS conjugates across the canalicular membrane into the bile canaliculi. 
This canalicular secretion occurs against a high concentration gradient and is facilitated by adenosine-
triphospate (ATP)-dependent transporters, the most important of which is the Bile Salt Export Pump 
(BSEP or ABCB11). 14,15 Via the bile canaliculi, BS are finally transported to the duodenum where they 
facilitate the solubilization of lipids. 
BS can be reabsorbed passively, but are mainly reabsorbed actively by the Apical Sodium-dependent 
BS Transporter (ASBT) 16 in the terminal ileum (overall ~95%). At the basolateral enterocyte membrane, 
BS leave the cells via the organic solute transporter (OSTα/β). 17 They are transported back to the liver 
through the portal system and are mostly taken up via the Na+-dependent Taurocholate Co-transporting 
Polypeptide (NTCP) at the basolateral hepatocyte membrane. 18 This process is called enterohepatic 
cycling (EHC). 9 Under physiological circumstances BS transport from hepatocyte into the bloodstream 
is negligible. However, this may rapidly change under cholestatic conditions, where BS are delivered to 
the blood via members of the Multi drug resistance Related Proteins (MRPs), such as MRP4/ABCC4. 19
The BS that escape absorption in the terminal ileum enter the colon. Primary BS can be deconjugated 
and converted to secondary BS species by the intestinal microbiota. Bacteria can convert β-MC to 
hyodeoxycholate (HDC) 20,21 and ω-MC. In addition, they are able to convert CDC to lithocholate (LC, 
mainly in humans) 22 or ursodeoxycholate (UDC) 23, and cholate to deoxycholate (DC) 22. A part of colonic 
BS is passively absorbed, while the remaining part is excreted with feces. Excretion of BS with feces 
actually represents an important pathway for cholesterol disposal. Under steady state conditions, the 
liver compensates for fecal BS loss by de novo BS synthesis.
BS regulate their own secretion and synthesis via an elaborate feedback pathway. 24 Hepatic BS activate 
the nuclear receptor (NR) farnesoid X receptor (FXR), which induces BS secretion via BSEP and reduces 
basolateral BS uptake via NTCP. 
After uptake in the terminal ileum, BS activate intestinal FXR which activates OSTα/β-mediated export 
of BS. FXR also induces the short heterodimer partner (SHP), resulting in release of fibroblast growth 
factor (Fgf ) 15 (mice) or FGF19 (humans) into the portal blood. 24 Fgf15/FGF19 activates the fibroblast 
growth factor receptor 4 (FGFR4) in the liver, which ultimately facilitates transcriptional inhibition of 
cholesterol 7 alpha-hydroxylase (Cyp7a1, encoding the rate-limiting enzyme for BS synthesis). 25 Both 
SHP and FXR lack a Cyp7a1 DNA binding site. Liver FXR is activated primarily by primary BS (mainly 
CDC), which induces SHP. SHP can activate the liver-related-homolog-1 (LRH-1, rodents) or α-fetoprotein 
transcription factor (FTF, humans). LRH-1/ FTF can bind the bile acid response element II (BARE-II) in the 
Cyp7a1 gene, inhibiting its transcription. SHP blocks the interaction between hepatocyte nuclear factor 
4α (HNF4α) and peroxisome proliferator-activated receptor γ coactivator 1 α (PGC1α), which also inhibits 
Cyp7a1 transcription via BARE-II. Cyp7a1 transcription can in addition be inhibited via steroid hormones, 
inflammatory cytokines, insulin, growth factors and NRs that operate independently of FXR. 26 LC is a 
ligand for the pregnane X receptor (PXR), constitutive androstane receptor (CAR; indirectly) and vitamin 





PXR and VDR bind the BARE-I and block recruitment of PGC1α, inhibiting Cyp7a1 transactivation by 
HNF4α. CAR binds the BARE-II and competes with HNF4α for several coactivators, including PGC1α. 26 
On the other hand, when the liver X receptor (LXR) is activated by oxysterols, transcription of Cyp7a1 is 
induced via the BARE-I in rodents (not in humans due to an alteration in the BARE-I sequence), resulting 
in production of BS from cholesterol. 24 
It is becoming more and more clear that BS are not just simple detergents necessary for lipid absorption, 
but are also involved in the regulation of glucose, lipid homeostasis as well as energy expenditure. 27 
Recent data show that removal of BS from the intestine with sequestrants can decrease plasma low 
density lipoprotein (LDL) levels and hyperglycemia in patients with type II diabetes. 28 The mechanisms 
by which the total pool size and/or profile of BS influence different physiological processes are only 
beginning to be understood. 
2. Dietary lipid absorption
2.1 Dietary fat absorption
Lipid absorption in general involves emulsification, lipolysis, micellar solubilization, uptake by mucosal 
epithelium, re-esterification, chylomicron (CM) formation and lipoprotein metabolism. 29 This paragraph 
will focus on dietary fat, whereas specific aspects of cholesterol absorption will be discussed in paragraph 
2.2. Triglycerides (also called triacylglycerols; TG) form the major lipid component in the human diet. 
Lipids are dispersed by chewing, which increases the surface area. In the stomach, partial hydrolysis by 
gastric and lingual lipase takes place (10-30% of TG) and diacylglycerol and free fatty acids (free FA) are 
released. 30,31 Pancreatic lipase facilitates further hydrolysis, producing monoacylglycerol and free FA. 32 
PL (from diet, bile and sloughed intestinal epithelial cells) are hydrolyzed by phospholipase A
2
, yielding 
lyso-PL and free FA. 33 The products of pancreatic lipolysis have limited solublility and need subsequent 
solubilization by BS and/or association with PL. 34,35 
Adjacent to the luminal surface of enterocytes, micellar dissociation is promoted by decreased pH (5.3-
6.0) 36 in the so-called unstirred water layer 37, allowing for diffusion of FA across the cellular membrane. 
FA can also be taken up by transporters such as FA transporter protein 4 (FATP4) and FA translocase (FAT/ 
CD36), but none of these transporters were shown to be critical for FA absorption. 38,39 
In the enterocyte, FA may bind to the intestinal FA binding protein (IFABP) and diffuse into the 
endoplasmatic reticulum. After activation acyl-CoAs are produced and re-esterified into TGs via 
several steps. 40 Microsomal TG transfer protein (MTP) assembles TG, PL and cholesterol together with 
apolipoprotein B48 (ApoB48) to form a CM particle or with ApoB100 (not in humans) to form a very low 
density lipoprotein (VLDL) particle, both of which are secreted to the interstitium via the basolateral 
membrane. 41 From the intestitium the particles enter lymphatic capillaries that drain into omental 




Cholesterol present in the intestinal lumen derives from several sources, including diet, bile, intestinal 
secretion and desquamated epithelial cells. In humans consuming Western type diets, 300-500 mg 
dietary cholesterol enters the intestinal lumen per day, whereas the contribution of biliary cholesterol 
has been estimated to be approximately 800-1200 mg per day. 42 Cholesterol is a hydrophobic molecule, 
and it intestinal absorption is facilitated via similar steps as described for FA (emulsification, hydrolysis of 
dietary esterified cholesterol, micellar solubilization, and uptake within enterocytes). In healthy humans 
normally approximately 50% of intestinal cholesterol is absorbed. 43 Micellar solubilization of cholesterol 
is essential for cholesterol absorption. 44 The physical chemistry of biliary cholesterol may influence its 
absorption in the intestine. Whereas micellar biliary cholesterol is readily available for absorption, dietary 
cholesterol first has to be released from food oils or tissue membranes. Elegant isotope infusion studies 
in rats, however, showed that only on high cholesterol diet dietary cholesterol is relatively malabsorbed 
compared with biliary cholesterol. 
On low and moderate cholesterol enriched diets micellized and non-micellized cholesterol appear 
in lymph in similar amounts. 45 Biliary cholesterol is unesterified, whereas dietary cholesterol is partly 
esterified. Dietary cholesterol esters (CE) thus must be hydrolyzed by pancreatic carboxyl ester lipase 
(CEL) before cholesterol can be transported into enterocytes. Howles et al. showed that dietary esterified 
cholesterol absorption was reduced by >60% in CEL-null mice, whereas absorption of free cholesterol 
was normal. 46 Considering the low daily supply of intestinal CE 47, hydrolysis of CE by CEL may not be 
critical for overall cholesterol absorption. CEL may however serve a function similar to phospholipase A
2
, 
in providing sufficient hydrolysis of PL (mainly phosphatidylcholine (PC), which is required for adequate 
micelle formation. For example, in rats drained of bile and pancreatic juice, administration of CEL 
enhanced lymphatic recovery of cholesterol infused into the duodenum as a micellar, PC containing, 
solution. 48 Moreover, CEL itself may be absorbed by enterocytes via endocytosis. 49 and the ceramidase 
activity of CEL has been implicated in proper intracellular cholesterol trafficking and CM assembly. 50 
In addition to cholesterol, a typical Western diet contains structurally similar phytosterols (including 
plant sterols (~95%) and stanols (~5%)), in similar amounts as cholesterol, depending on the diet. 
Plant sterols and stanols inhibit the absorption of cholesterol, however the mechanism(s) by which they 
do so remain a matter of discussion (see paragraph 5.3.2). Uptake of cholesterol and plant sterols and 
stanols is believed to be facilitated by the Niemann-Pick C1 Like 1 (NPC1L1) transporter 51, which is 
located in the brush border membrane of enterocytes in the proximal (jejunum), but not the distal 
(ileum) small intestine. Npc1l1 null mice showed 70% and 90% reduction in cholesterol and plant sterol/
stanol absorption, respectively, compared with control mice. 52,53 
In addition, Npc1l1 null mice showed upregulation of intestinal and hepatic HMG-CoA synthase mRNA 
and intestinal cholesterol synthesis. 53 In the proximal small intestine (and apical hepatocyte membrane), 
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Figure 1. Cholesterol transporters, converting enzymes and lipoproteins in liver and intestine. A: Cholesterol in 
enterocytes originates from absorption, synthesis and uptake from the circulation. Cholesterol and plant sterols/ 
stanols are absorbed from the intestinal lumen via NPC1L1 and secreted back to the lumen via ABCG5/G8. Intracellular 
cholesterol and plant sterols/ stanols can be esterifi ed by ACAT2, packaged into apoB48 containing CM by MTP, 
and secreted to the lymph. Alternatively, cholesterol can be secreted via ABCA1 in ApoA1 containing HDL particles. 
Uptake of cholesterol on the basolateral side occurs via SR-B1 (HDL-c) and LDLR (LDL-c), which recognizes ApoB100. 
B: The liver takes up HDL-c via SR-B1 and ApoE containing CR-c via LRP1 and the LDLR. In the hepatocyte ACAT2 
esterifi es cholesterol and CE are reassembled into VLDL particles together with CR-derived products. VLDL particles 
contain apoB100 instead of apoB48. ApoB100 binding to MTP results in loading of lipids to the VLDL particle. 
The liver secretes the VLDL particles into the circulation for delivery of lipids to the periphery. VLDL is in part cleared by 
the hepatic LDLR, whereas the rest is transformed to IDL and LDL, which still contain apoB100 necessary for reuptake 
in the hepatocyte via the LDLR. The liver secretes cholesterol to bile via ABCG5/G8 and transforms cholesterol to BS, 
which are secreted via BSEP. Hepatic NPC1L1 can facilitate reuptake of biliary cholesterol. 
Abbreviations: ACAT2: acyl CoA:cholesterol acyltransferase 2, CM: chylomicrons, CR: chylomicron remnants, LRP1: 
LDLR-related protein 1, MTP: microsomal triglyceride transfer protein, CE: cholesteryl esters, BS: bile salts, BSEP: bile 
salt export pump.
Effl  ux of unesterifi ed cholesterol and plant sterols and stanols from the enterocyte back to the intestinal 
lumen, as well as biliary cholesterol secretion are facilitated by ABCG5/G8. 54,55 Intracellular cholesterol 
that is not effl  uxed by ABCG5/G8 travels to the endoplasmatic reticulum, where it is esterifi ed by acyl 
CoA:cholesterol acyltransferase 2 (ACAT2). 56 When LXR is activated, it forms a heterodimer with the 
Retinoid X receptor (RXR) and the complex induces transcription of target genes encoding proteins 
involved in cholesterol disposal, including the two half-transporters ATP-binding cassette sub-family G 
member 5 and 8 (Abcg5/ Abcg8). 57 Transcription of Npc1l1 on the other hand is downregulated upon 
LXR activation. This likely repesents an indirect eff ect, since LXR is not known as a direct repressor. 24 
Intracellular cholesterol is partly re-esterifi ed and fi nally delivered to the bloodstream, mainly as 
component of CM, together with TG, PL and apoB48, for transport to the lymph. MTP regulates this 
process, and also facilitates VLDL formation after cholesterol esterifi cation by ACAT2 in hepatocytes. 58 
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In addition, enterocytic cholesterol can be transferred to apoAI high density lipoprotein (HDL) particles 
via ABCA1 (basolaterally located in enterocytes; figure 1). 59 
Up to now, only NPC1l1 seems to be critical for apical intestinal cholesterol import. 52,53 Studies, in which 
proposed alternative candidates, such as scavenger receptor class B member 1 (SR-B1), CD36 and 
caveolin-1, were eliminated, showed that none of these proteins was crucial for cholesterol uptake. 60-64 
ABCA1 was implicated in cholesterol absorption in the past. However, unchanged fecal sterol excretion 
in Abca1-/- mice indicated that ABCA1 plays no role in control of cholesterol absorption. 65 
In vitro studies suggested a possible role for aminopeptidase N (CD13) in cholesterol absorption 66 which 
has not yet been confirmed in in vivo studies. In contrast to ABCA1, ACAT2 and MTP do affect cholesterol 
absorption (paragraph 5.3). 
Cholesterol homeostasis
Disturbances in cholesterol homeostasis are associated with potential life-threatening consequences. 
Hypercholesterolemia promotes atherosclerosis and thereby represents a major risk factor for 
cardiovascular disease. 67,68 Pharmacological inhibition of cholesterol synthesis has been the most potent 
treatment option for hypercholesterolemia during the last decades. Cholesterol synthesis inhibition by 
itself however, can reduce the risk of cardiovascular disease by only a third. 69 This underlies the ongoing 
search for alternative therapeutic modalities. 
The liver has been considered the major site of control in maintenance of cholesterol homeostasis. 70 The 
liver facilitates clearance of VLDL/ LDL particles and cholesterol-containing CM remnants, synthesizes 
cholesterol, synthesizes and secretes (nascent) HDL particles, secretes cholesterol and BS to bile and is 
involved in reverse cholesterol transport (RCT). 7 
RCT is classically defined as the process by which cholesterol from peripheral tissues is transported to 
the liver, followed by excretion via bile to feces in the form of neutral sterols and BS. In recent years, 
however, the importance of the intestine in many aspects of cholesterol physiology is increasingly 
recognized. The intestine has a major impact on cholesterol homeostasis at the level of cholesterol (re-)
absorption, fecal excretion and de novo synthesis. 71 It has become apparent that, at least in mice, direct 
secretion of cholesterol from the blood compartment into the intestine, i.e. TICE, plays a major role in 
disposal of cholesterol via the feces. 72 
It would be desirable to induce fecal cholesterol loss via the intestine without increasing biliary 
cholesterol secretion and thereby the risk of cholesterol gallstones. 73 
3. Transport of cholesterol through plasma
A plethora of epidemiological studies have unequivocally shown that increased plasma cholesterol 
levels are associated with cardiovascular disease risk. Interestingly this does not necessarily coincide 
with increased tissue cholesterol, but is probably caused by changes in rates of secretion and uptake of 





The type of lipoprotein is determined by its buoyant density and apoprotein composition, which act as 
emulsifying coating and target their metabolism. 75 
There are marked differences in lipoprotein metabolism between humans and rodents. For example, 
mice do not possess cholesterol-ester transport protein (CETP) and have an up to 40-fold higher LDL 
clearance by the liver compared to humans. 70,76 Mice carry most of their plasma cholesterol in HDL 
particles and as such are not a good model for human disease. 70,76 
This is the reason why many studies on cholesterol metabolism have been performed in mice with 
genetic deficiency of major determinators of plasma cholesterol metabolism such as the Ldl receptor 
(Ldlr) 77 or ApoE 78. More recently “humanized” mice have become available in which human CETP 
79 is expressed. On an Ldlr null or ApoE3 Leiden background these mice mimic many aspects of the 
hyperlipidemic human phenotype. 80,81 Inhibition of CETP increases HDL and should ameliorate 
atherosclerosis, but clinical trials with the first CETP inhibitor (torcetrapib) were terminated because of 
adverse off-target effects (increased mortality and cardiovascular events). 
Recently, a new CETP-related drug (dalcetrapib) showed lack of a clinically meaningful benefit in a clinical 
trial, and further testing of the drug has been halted.82 Until now, inhibition of cholesterol synthesis has 
remained the first line of therapy for hypercholesterolemia.
4. Cholesterol synthesis
4.1 Control of cholesterol synthesis 
Cholesterol is synthesized from its precursor unit acetyl-CoA via a complex metabolic pathway 
summarized in figure 2. 83,84 HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis 85. 
Recently squalene monooxygenase, which catalyzes the first oxygenation step in cholesterol synthesis, 
was suggested to represent a possible second control point in cholesterol synthesis beyond HMG-
CoA reductase. 86 Cholesterol and fat biosynthesis are under control of a family of transcription factors 
designated Sterol Regulatory Element Binding Proteins (SREBPs). Three isoforms of SREBP have been 
described, i.e., SREBP1a, SREBP1c and SREBP2. Genes encoding enzymes and tranporters involved in 
cholesterol absorption and efflux are under tight transcriptional control (reviewed recently by 57). 
Cholesterol and its biologically active metabolites act as ligands for NR that regulate gene expression. 
LXR is a major regulator of cholesterol metabolism. 57 When sterols are present in excess intracellularly, 
LXR-mediated activation of SREBP1c transcription leads to induction of oleic acid synthesis. Oleic acid 
is the preferred FA for the synthesis of cholesterol esters (CE), which can be stored intercellularly. LXR 




Figure 2. Cholesterol biosynthesis pathway. Cholesterol is synthesized from its precursor unit acetyl-CoA (Ac-
CoA). Two acetyl-CoAs are condensed, forming acetoacetyl-CoA (AcAc-CoA). AcAc-CoA and a third acetyl-CoA 
are converted to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) by the action of HMG-CoA synthase. HMG-CoA is 
converted to mevalonate by HMG-CoA reductase. Mevalonate is subsequently converted to an isoprenoid molecule, 
isopentenyl pyrophosphate (PP), with the concomitant loss of CO
2. 
Geranyl-PP and farnesyl-PP are produced from 
isopentenyl-PP. Two farnesyl-PP subunits are combined to form squalene. Squalene is converted to lanosterol and 
subsequently cholesterol via many intermediates, including zymosterol, desmosterol and lathosterol. Solid line: direct 
step. Dashed line: product is formed via intermediate steps.
Cholesterol synthesis is tightly regulated by SREBPs (mainly type 2). When cellular cholesterol is high, 
SREBP2 is located to the ER in a complex with SREBP2 cleavage–activating protein (SCAP). When cells 
are depleted of sterols, SCAP escorts SREBP2 from the ER to the Golgi apparatus, where it is cleaved 
in order to release part of the protein from the membrane. SREBP2 then can enter the nucleus, bind 
to a sterol response element (SRE) in the enhancer/ promoter region of many target genes involved 
in cholesterol synthesis, and activate their transcription. 87 The importance of cholesterol synthesis for 
survival is illustrated by the fact that defects in the cholesterol synthesis pathway are generally lethal in 
mice. Complete loss of function of early cholesterogenic enzymes is rarely described in humans and 
deficiencies of these enzymes lead to severe malformations and disease.88
4.2 Measurement of cholesterol synthesis in vivo
The different methods available to determine cholesterol synthesis in vivo include sterol balance, 
(plasma) cholesterol precursor measurement and tracer incorporation techniques [such as deuterium 





An early approach to estimate cholesterol synthesis has been cholesterol balance: measurement of 
cholesterol and BS excretion in feces followed by subtraction of dietary cholesterol intake yields whole 
body synthesis. Surrogate serum markers of cholesterol synthesis (and absorption) will be discussed 
in section 3. Here we will briefly discuss the two more recently developed and refined methods: 
DI and MIDA. The DI (2H) method has a similar background as the tritiated (3H) water method used 
in experimental animals. The theory behind the method is described below. Deuterated water can 
equilibrate in total body water and NADPH. Enrichment of deuterium in plasma water, representing 
the precursor pool, and deuterium enrichment of cholesterol in either plasma or red blood cells can be 
determined sensitively by isotope ratio mass spectrometry. 
Eighteen acetyl CoA units containing 36 carbon (C) atoms are utilized to synthesize one molecule of 
cholesterol, which contains 27 C atoms and 46 hydrogen (H) atoms. During synthesis of a cholesterol 
molecule, 7 H atoms are incorporated originating directly from water, while another 15 H atoms are 
inserted from nicotinamide adenine dinucleotide phosphate-oxidase (NADPH). 
H atoms from water may also become incorporated into substrates that, later on, are used for the 
generation of the cytosolic acetyl CoA pool that is used for cholesterol synthesis. If no labeled H from 2H 
water were incorporated into these precursors of the cytosolic acetyl CoA pool, and if the reductive H of 
the NADPH were derived entirely from unlabeled sources, only 7 labeled H atoms (those orginating from 
the administered 2H water) could be found in each newly synthesized cholesterol molecule (minimal 
theoretical labeled H/C incorporation ratio would be 7/27). Alternatively, if NADPH fully equilibrates with 
2H labeled water, then a final labeled H/C incorporation ratio of 22/27 would be found. This is considered 
the maximal labeled H/C ratio in short term measurements. 90 On the long run, an even greater value 
might be obtained when there is significant incorporation of labeled H into an important acetyl-CoA 
precursor, which by then has been used for cholesterol synthesis. 
On a theoretical basis it is difficult to predict exactly how many labeled H atoms will be incorporated 
into each cholesterol molecule. Labeled H/C ratios are not available for all organs. In short term in 
vivo studies in mice and rats, 21-25 tritiated H atoms were incorporated into cholesterol molecules of 
whole carcass, liver or brain per C atom entering the biosynthetic pathway as acetyl CoA 90 and these 
values were subsequently used in other studies to calculate absolute cholesterol synthesis. However, 
combining the DI method with MIDA (discussed below) in long term experiments (up to 8 weeks), the 
maximum incorporation number in rat liver was found to be 30. 91 This could mean that earlier studies 
have overestimated true cholesterol synthesis rates. Many human studies using the DI method have 
used H incorporation values obtained from literature 92 and thus provide rough estimates of absolute 
cholesterol synthesis rates. 
With MIDA the precursor-pool enrichment, fractional synthesis, and absolute (whole body) synthesis 
of cholesterol are calculated based on the pattern of excess enrichment among mass isotopomers of 
cholesterol present in plasma after administration of stable isotope-labeled 13C-acetate. 93 
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The distribution of abundances in newly formed cholesterol molecules, measured by gas-
chromatography-mass spectrometry, allows calculation of the abundance in the precursor. MIDA thus 
eliminates the need to measure the precursor pool enrichment directly. 
Knowing the true precursor-pool enrichment allows calculation of the fractional and absolute cholesterol 
synthesis rates. MIDA reveals the weighted mean abundance of the precursor pools contributing to the 
product mixture. 94 
In the past, human as well as animal studies applying MIDA were performed in relatively short time 
frames, which could underestimate whole body synthesis due to circadian effects and/or incomplete 
equilibration of the free cholesterol pool. A human study showed that the DI method and MIDA yield 
similar rates of fractional and absolute cholesterol synthesis when measured over at least 24h. 95
4.3 The body cholesterol pools
A complication when assessing de novo cholesterol synthesis is the existence of different pools of 
cholesterol in the body with a differential rate of exchange. To incorporate this aspect, the turnover 
of plasma cholesterol has been modeled by dividing total body cholesterol into 2 or 3 exchangeable 
pools. 92,93 
In the 3-pool model, pool 1 (rapidly miscible) is considered to consist of cholesterol in fairly rapid 
equilibrium with plasma cholesterol (plasma, blood cells, liver and intestines), pool 2 consists of 
cholesterol that equilibrates at an intermediate rate (visceral and peripheral tissues) and pool 3 
represents the slowest cholesterol turnover compartment (adipose and connective tissue, skeletal 
muscle and arterial walls). 
The 3-pool model has been used for long term studies (up to 48 weeks). 92 Differentiation between pools 
2 and 3 in short term experiments appeared not essential for accurate mathematical modeling. Pool 1 in 
the 2-pool model represents the rapidly exchangeable pool similar to that in the 3-pool model, whereas 
pool 2 of the 2-pool model represents a combination of pool 2 and 3 of the 3-pool model. 93 
The central nervous system contains a major part of total body cholesterol (15% and 23% in mice and 
humans, respectively). There is no detectable uptake of plasma cholesterol into the brain via the blood-
brain-barrier. 96 The central nervous system presumably excretes only a very small amount of cholesterol 
to pool 3 under physiological conditions. Thus, it must be kept in mind that brain synthesis is not taken 
into account when calculating whole body cholesterol synthesis. 
In general, whole body cholesterol synthesis rates measured using either the DI method or MIDA were 
shown to be comparable with those reported with the classical cholesterol balance (cholesterol intake 
+ synthesis = fecal excretion of BS + neutral sterols). 93,97
4.4 Regional and whole body cholesterol synthesis
Virtually every mammalian cell synthesizes cholesterol, in most animals the main part being synthesized 
in extrahepatic organs. 70,98,99 Whole body synthesis and the contribution of liver and intestine to whole 





A complication in evaluating the value of these measurements is the circadian rhythm of cholesterol 
synthesis, which has not always been taken into account (see below). It seems justified to conclude 
that species such as hamsters, guinea pigs, rabbits and squirrel monkeys and humans have much lower 
synthesis rates than rats and mice. 
The gastrointestinal tract contributes around 15-35% to total cholesterol synthesis in experimental 
animals. In rodents, the contribution of the liver to whole body synthesis at night has been shown to 
vary from as low as ~15-20% in rabbits and guinea pigs to as high as 50% in rats. 70 In humans the liver 
is thought to contribute only around 10% to whole body synthesis 70 (~10 mg/kg/d). Low rates of local 
synthesis relative to the rates of uptake of newly synthesized cholesterol from blood in rats were found 
in adrenal glands, spleen, lung and kidneys. These organs increase their cholesterol synthesis when 
circulating levels of plasma cholesterol are decreased. 99 
4.5 Influence of diet and time of day on cholesterol synthesis
Whole body as well as organ specific cholesterol synthesis rates vary depending on the presence of 
cholesterol and other lipids in the diet. Dietary cholesterol suppresses hepatic cholesterol synthesis. In 
rats fed no dietary fat, liver synthesis rates are decreased when feeding a 2% cholesterol containing diet, 
while synthesis rates in the intestine and other extrahepatic tissue remain similar, suggesting that only 
the liver senses the increase in cholesterol uptake. 100 Adding cholesterol to either a low or high fat diet 
also leads to decreased hepatic cholesterol synthesis in hamsters. 101 
It appears that dietary fat alone however does not affect hepatic and whole body cholesterol synthesis, 
but can induce intestinal cholesterol synthesis. This was illustrated by several studies. First of all, on a high 
fat compared with low fat diet, hepatic cholesterol synthesis is comparable in hamsters. 101 In addition, 
it was shown in mice on a 0.2% cholesterol diet that dietary short, medium and long chain fatty acids 
did not differentially affect extrahepatic cholesterol synthesis. 102 Infusion of corn oil in non-cholesterol, 
non-fat fed rats increases cholesterol synthesis in the intestine, while liver synthesis remains the same. 100 
A high fat diet in hamsters also increases cholesterol synthesis in the intestine in the presence of dietary 
cholesterol, however whole body synthesis is not affected 103.
In addition to dietary fat and cholesterol content, the type of diet influences cholesterol synthesis 
rates. These were shown to be lower on purified diets as compared to non-purified diets. 104,105 Energy 
restriction per se seems to have the greatest (lowering) effect on cholesterol synthesis (reviewed by 89). 
Both animals and humans display a circadian rhythm of cholesterol synthesis, with a peak in synthesis 
several hours after feeding. Most studies on cholesterol turnover in experimental animals have been 
performed during the dark phase of the light cycle. 106 It must be kept in mind that cholesterol synthesis 
is 2-3 fold higher during the (end of the) dark phase compared to the light phase. 93,107,108 In extrahepatic 
tissues the difference between day and night in cholesterol synthesis is much smaller compared with 
the liver, at least in mice. 107 Circadian rhythm in the liver is controlled by different molecular mechanisms, 
including cAMP-dependent and CLOCK/ BMAL1 regulation, which for example regulate expression of 
cholesterol synthesis genes Hmgcr, Hmgcs, Sqs, Fpps and Cyp51. For details, see ref. 109-111.
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4.6 Targeting cholesterol synthesis in hypercholesterolemia
HMG-CoA reductase inhibitors (statins) have been used successfully to inhibit cholesterol synthesis and 
reduce all-cause mortality since the late 1980’s. 112 Reduced hepatic cholesterol is compensated for by 
synthesis of LDLR to draw cholesterol out of the circulation 113 leading to lowering of plasma cholesterol 
levels. Some statins (pravastatin) seem to preferentially inhibit synthesis in liver and intestine (90%) 
114,115 compared with synthesis in extrahepatic organs, such as kidneys (73%), testes (55%), lungs (53%), 
spleen (53%) and adrenals (49%). 114 Other statins (lovastatin) exhibit widespread cholesterol synthesis 
inhibition. 116 This may be mainly due to differences in cellular uptake 115, which can be caused by 
differences in lipophilicity, pH-sensitivity, plasma protein binding, activity of metabolites and transporter 
facilitated uptake and export. For example, simvastatin and lovastatin are administered as very lipophilic 
(tissue penetrating) lactone prodrugs, whereas other statins are administered in their active form. 117 
Different statins have different affinities for import proteins of hepatocytes such as organic anion 
transporting polypeptides (OATP) and NTCP. 118-121 In addition, polymorphisms in these transporters 
differentially affect statin uptake and (in vitro) affinity for transporters can differ between human and 
experimental animal cells. 121
Although highly effective, statins do not produce the desired health effect in a significant group of 
patients and can cause severe side effects such as myalgia and myopathies (rhabdomyolysis), 122 in 
particular in case of polypharmacy. Statins decrease farnesyl and geranyl pyrophosphate (isoprenoids) 
and dolichol synthesis, reducing essential post-translational prenylation and N-linked glycosylation of 
proteins. This may result in myocyte and hepatocyte cell damage and even cell death. 123,124 Newer statins, 
such as the recently approved pitavastatin, with a distinctive metabolic profile, may display a reduced 
incidence of these adverse effects. 125 In addition, efforts are ongoing to produce new drugs targeting 
cholesterol synthesis at different levels of the pathway. Squalene synthase inhibitors for example 
increase farnesyl diphosphate while decreasing cholesterol synthesis. They are able to prevent statin 
induced changes in protein farnesylation and cell death in vitro. 124 Since these inhibitors do not target 
true rate-limiting steps in cholesterol synthesis, they may not effectively reduce cholesterol synthesis as 
a monotherapy in tolerable dosages.
Variations in efficacy of statins can be caused by many factors, including race (genetics), body weight 
and diet. Humans that inherently have lower cholesterol synthesis rates may respond less adequate to 
statin treatment. LDL-cholesterol (LDL-c) response to statins is lower in black compared to white people, 
which is associated with lower baseline LDL-c and variant haplotypes of the HMG-CoA reductase gene 
in black people. 126 Statins may induce expression of proprotein convertase subtilisin-like kexin type 
9 (PCSK9) and SREBP2. PCSK9 is a circulating protein that impairs LDL clearance by promoting LDLR 
degradation. PCSK9 thus could diminish statin efficacy, hence PCSK9 inhibitors are currently tested in 
clinical trials. 127 
In general, cholesterol synthesis inhibition leads to a reciprocal increase in cholesterol absorption, 128 
which has led to elaborate research to develop cholesterol absorption inhibitors (discussed below). With 
growing knowledge on the determinants of response to cholesterol lowering therapy, in the future it 





5. Measurement and inhibition of cholesterol absorption
5.1 Measurement of cholesterol absorption in vivo
The available methods to measure cholesterol absorption in humans and mice include (radiolabeled or 
stable) isotope based methods (fecal and plasma dual isotope method), intestinal perfusion and blood 
levels of surrogate markers such as plant sterols and intermediates of cholesterol synthesis. Details can 
be found in several reviews. 129,130 The intestinal perfusion method is the only method that can directly 
quantitate absorption of intestinal cholesterol in humans. 131,132 Widespread use of this method is limited 
by the need for intubation and radiation exposure. 
The dual isotope ratio method has been optimized using stable instead of radioactive isotopes both in 
the plasma (ratio of intravenously and orally administered labeled cholesterol) 133 and fecal (ratio of orally 
administered labeled cholesterol and sitostanol in feces) dual isotope ratio method. 134 The fecal dual 
isotope ratio method is limited by requirement of 72h feces collection. The plasma dual isotope ratio 
method has been limited by measurement of single time point absorption, however this method can 
nowadays be applied for longer periods, at least in mice. 135 
The only approach available to easily estimate (relative) changes in cholesterol absorption in large scale 
studies is to measure plasma surrogate markers. These include the ratio of plant sterols (campesterol 
and sitosterol) or cholestanol (cholesterol metabolite) to cholesterol in plasma. 136 Surrogate makers 
have shown to be valuable to answer questions related to changes in cholesterol absorption during 
treatments. However, dietary factors (fat, cholesterol, plant sterols and stanols 137, drugs (statins) 138 and 
metabolic diseases (diabetes mellitus) 139,140 can disturb correct interpretation of surrogate markers levels. 
For example, the reduction in plasma LDL-c correlates poorly with baseline levels of noncholesterol sterol 
markers of absorption (campesterol) and synthesis (lathosterol) in African- and European-American men 
treated with ezetimibe (a cholesterol absorption inhibitor, discussed in paragraph 3.3.1), simvastatin or 
a combination of the two drugs. 141 Similarly, although ezetimibe + simvastatin treatment significantly 
reduces campesterol and sitosterol levels in patients with familial hypercholesterolemia, baseline 
cholesterol absorption status does not determine LDL-c lowering response to ezetimibe + simvastatin 
therapy. 142 It is currently recommended to use several rather than one serum marker, if possible in 
addition to absolute measurements. 143
5.2 Targeting cholesterol absorption in hypercholesterolemia
Statin therapy is not sufficient to prevent cardiovascular disease risk in a substantial proportion 
of individuals. 144 To increase treatment efficacy considerable interest has arisen in dietary and 
pharmacological interventions that inhibit cholesterol absorption, possibly for combining this with 
inhibition of cholesterol synthesis . Most agents are nonspecific and require consumption in high daily 
quantities while modestly lowering plasma LDL-c. ACAT2 deficiency resulted in cholesterol malabsorption 
in mice, however only in cholesterol fed and not in chow fed mice. 145 MTP inhibition normalized plasma 
lipoprotein levels in a rabbit model for human homozygous familial hypercholesterolemia. 146 
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However, this process is related to disturbed CM formation, not specific for absorption of cholesterol 
and not intestine specific as it induces fat accummulation in the liver. 146 We will not discuss inhibition 
of these intracellular factors. Ezetimibe represents an exception, as it relatively specifically decreases 
cholesterol absorption. The impact of dietary plant sterols and stanols is discussed since it has become 
apparent very recently that they might have an unexpected intestinal effect (see section 6). Other 
cholesterol lowering food components are discussed elsewhere 147
5.2.1 Ezetimibe
Specific inhibition of cholesterol absorption, either from biliary or dietary origin, is accomplished after 
binding of ezetimibe to NPC1L1. 148 The compound is first glucuronidated in the intestine before 
travelling to the liver via the portal vein. Glucuronidated ezetimibe blocks the internalization of the 
NPC1l1/ cholesterol     complex 149 but does not block cholesterol absorption completely. 
In the Npc1l1 null mouse there is residual cholesterol absorption, indicating that another pathway of 
cholesterol absorption must exist. Ezetimibe does not inhibit this residual cholesterol absorption in 
Npc1l1 null mice, indicating that this residual pathway is ezetimibe independent. 52 
Studies in experimental animals indicated that ezetimibe may decrease absorption of vitamin E 
(α-tocopherol), but not vitamin A and D. 150,151 However, ezetimibe did not seem to affect fat soluble 
vitamin status in patients. 152,153 Ezetimibe can decrease plasma TG concentration. This does not seem to 
be absorption dependent, but rather a secondary effect of ezetimibe induced hepatic LDLR expression 
and subsequent increased clearance of ApoB100 and ApoB48 containing lipoproteins, particularly 
during co-treatment with statins. 154
In humans, ezetimibe alone decreases cholesterol absorption by 54% and decreases plasma LDL-c 
by ~19%, but increases whole body synthesis by 89%. 43 Combined treatment with statins for 
hypercholesterolemia, should therefore be very effective. 155 Recently however, the effect of combination 
therapy has become controversial. Some trials reported no additive effect of ezetimibe or even a worse 
atherosclerosis outcome when ezetimibe is added to patients previously treated with statins. 156 Others 
report increased efficacy of combination therapy over statin monotherapy, however data are limited 
to the level of serum lipid profiles. 157-160 Due to the lack of well-executed long term trials it is presently 
unclear whether combination therapy is better than increasing statin dosage. In the future, ezetimibe 
may be prescribed in patients in whom statin therapy is inadequate or intolerated. As monotherapy 
ezetimibe may improve postprandial hyperlipidemia and endothelial dysfunction. 161 In the presence of 
pancreatic dysfunction, CEL inhibitors may provide additional inhibition of cholesterol absorption when 
co-administered with ezetimibe. 150
5.2.2 Plant sterol/ stanol supplementation
In contrast to cholesterol, plant sterols and stanols can not be synthesized by the body and are poorly 
absorbed (plant sterols 0.4-3.5% and plant stanols 0.02-0.3%). 162 Fractional absorption of different plant 





The role of ABCG5/G8 in intestinal and hepatobiliary efflux of plant sterols and stanols versus cholesterol 
is not completely clear. In vitro studies showed comparable effectiveness of plant sterol and cholesterol 
transport via ABCG5/G8. 164 However, loss of ABCG5/G8 function in mice results in hyperabsorption of 
plant sterols and stanols, but not cholesterol, implying that ABCG5/G8 is more important for efflux of 
plant sterols and stanols compared to cholesterol. 165 In contrast to cholesterol, plant sterols and stanols 
are poor substrates for ACAT2 166, which seems to be the major factor limiting their absorption. Plant 
sterols and stanols effectively lower plasma LDL-c levels in adults as well as children with (familial) 
hypercholesterolemia. 167 
Plant sterols and stanols naturally occur in foods such as oils, (wheat) cereals, nuts and seeds. There are 
large differences in plant sterol/stanol consumption throughout the world, within the Western population 
and particularly between vegetarians and meat consumers. 168 Plant sterols/stanols are added to food 
products such as margarine, yoghurt and juices. To enable emulsification, added plant sterols/tanols are 
often esterified and require hydrolysis before being able to compete with cholesterol for absorption. 
It was recently suggested that the hydrolysis products of esterified plant sterols/ stanols (stigmasterol 
and especially saturated stearic acid) together may be more effective at lowering cholesterol micellar 
solubility than free plant sterols/stanols alone. 169 
The mechanism via which plant sterols and stanols lower plasma cholesterol does however not seem 
to be confined to decreasing cholesterol solubilization in the intestinal lumen. A recent meta-analysis 
showed that despite differences in absorption, plant sterols and plant stanols have similar effects on 
plasma lipid profiles. 170 Smaller repeated doses (3 times 0.6 g/d) of plant sterol/ stanol margarine as well 
as a single high daily dose (1.8 g/d) are equally effective at lowering cholesterol absorption and plasma 
LDL-c. 171 
Given that plant sterols and stanols are taken up in enterocytes, it was hypothesized that cholesterol 
absorption may be decreased by plant sterols/ stanols via increased cholesterol secretion to the 
intestinal lumen, for example via ABCG5/G8 under transcriptional control of the Liver X Receptor (LXR). 
However, Abcg5/g8 and Lxr knock-out mice did not reveal any change in cholesterol absorption 172-174, 
implying that others factors are involved. 
The combination of plant sterols with ezetimibe did not show an additive effect on (surrogate markers 
of ) cholesterol absorption and plasma LDL-c in mildly hypercholesterolemic subjects in an open-label 
study which was not controlled for dietary plant sterol and stanol content. 175 A recent randomized, 
double-blind, placebo-controlled, triple cross-over study on the other hand showed that plant sterols 
and stanols further reduced cholesterol absorption (fecal dual isotope method) and further increased 
fecal sterol excretion compared with ezetimibe alone in mildly hypercholesterolemic subjects 176,177. This 
study showed that the combination of statin and plant sterols and stanols exerted a minor additional 
effect on plasma LDL-c levels. Further studies in severe hypercholesterolemic patients may provide 
additional information on the usefulness of plant sterol/ stanol-ezetimibe combination therapy. 
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An adverse effect of plant sterol and stanol consumption could be disturbed micellar incorporation 
and absorption of fat-soluble vitamins.178,179 The long term potential adverse effects of plant sterols and 
stanols, such as increased atherogenesis and tissue (liver, brain) accumulation of plant sterols and stanols 
may seem negligible, but await further study. 168,180
6. Cholesterol excretion
6.1 Classical Reverse Cholesterol Transport (RCT) 
The body can dispose itself from cholesterol predominantly in two ways: as neutral sterols (cholesterol 
and its intestinal bacterial degradation metabolites) or as acidic sterols (BS). Cholesterol and BS are 
excreted mostly with feces and only minimal amounts of cholesterol are additionally lost via the skin. The 
classic view of RCT includes the flux of cholesterol from peripheral tissues to the liver mediated mainly 
by HDL particles, and the subsequent secretion of this cholesterol by the liver in bile that is transported 
to the intestinal lumen, leading to fecal excretion of cholesterol. 
Hepatobiliary RCT for decades has been considered the main, if not the only, pathway for cholesterol 
elimination. We will briefly discuss this pathway and then turn to other, more recently identified 
pathway involved in cholesterol excretion.The liver plays an important role in cholesterol homeostasis 
by regulating uptake of lipoproteins, cholesterol synthesis and cholesterol secretion (figure 1). Uptake of 
cholesterol is facilitated primarily via basolateral LDLR (LDL and VLDL uptake) and SR-B1 (HDL uptake). 
Cholesterol is basolaterally secreted from hepatocytes to the plasma compartment in VLDL and HDL 
particles and apically from hepatocytes to bile either directly as free cholesterol (via ABCG5/G8) or after 
conversion to BS (via the BS export pump (BSEP or ABCB11) 181 Biliary BS secretion is the main driving 
force for secretion of cholesterol and PL. However, studies in mice in which the PL transporter multi-
drug resistance P-glycoprotein (Mdr2 or Abcb4) was eliminated 182, showed that PL secretion itself is also 
required for cholesterol secretion. 
Cholesterol as well as plant sterols and stanols are secreted into bile mainly via ABCG5/G8. 
Recent studies of mice with altered hepatic expression of Niemann-Pick C2 (NPC2, a cholesterol-binding 
protein that is involved in intracellular cholesterol trafficking in hepatocytes, but can also be secreted 
to bile 183) revealed that NPC2 may positively regulate the biliary secretion of cholesterol, which was 
supported by the correlation between levels of NPC2 protein and cholesterol in human bile. Secreted 
NPC2 appears to specifically stimulate ABCG5/G8-mediated cholesterol efflux. It was suggested that 
NPC2 binds cholesterol and thereby accelerates the transfer of cholesterol to micelles via ABCG5/G8. 183 
In recent years it has become clear that the definition of RCT needs revision. 184 Elimination of cholesterol 
via feces, at least in mice, mainly occurs not via the classical hepatobiliary route, but via an alternative 





6.2 Transintestinal Cholesterol Excretion
6.2.1 The concept of TICE
The TICE concept has been reviewed recently. 8,73,184,185 Here we will briefly describe the pathway 
and latest insights in its dynamics. It was shown in several mouse models with extremely low biliary 
cholesterol secretion rates (inactivation of Abcg5, Abcg8 or Abcg5/g8 and Mdr2 or overexpression of 
hepatic Npc1l1, see figure 3), that fecal neutral sterol excretion was unchanged or even increased 186-190. 
This could not be explained by increased fecal loss of newly synthesized intestinal cholesterol. 191 At a 
stable dietary cholesterol intake, this suggested that cholesterol could be excreted directly from blood 
to feces via the intestinal mucosa.
Figure 3. Schematic presentation of cholesterol input and excretion in several mouse models. Mice deficient in 
Abcg8 or Mdr2 have extremely low biliary cholesterol secretion rates, however fecal neutral sterol excretion is 
relatively similar (Abcg8-/-) or even increased (Mdr2-/-). Similarly, in wildtype mice treated with an LXR-agonist the sum 
of dietary and biliary cholesterol secretion is outleveled by fecal cholesterol excretion. These models provided the first 
evidence for the existence of transintestinal cholesterol excretion in mice. 
Definitive indications for the existence of TICE were obtained in intestinal perfusion studies in which the 
bile duct was ligated and the absence of biliary components was compensated for by infusion of several 
(cholesterol free) model bile solutions. Van der Velde et al. demonstrated that TICE occurs in the entire 
small intestine, but particularly in the proximal part and plays quantitatively a more prominent role than 
the hepatobiliary route in mice. Importantly, intestinal cell shedding and synthesis could not account for 
the secreted cholesterol. 187,191 Brown et al. showed that mice with a targeted deletion of hepatic ACAT2 
have normal biliary cholesterol secretion rates, in the presence of doubled fecal cholesterol excretion. The 
authors determined the fate of newly secreted liver-derived cholesterol. For this purpose, hepatic sterol 
pools were radiolabeled and nascent hepatic cholesterol-labeled lipoproteins were collected by isolated 
liver perfusion. The liver-derived lipoproteins were then re-injected intravenously into hepatic ACAT2 
deficient and control mice to examine the movement of liver-derived radiolabeled cholesterol. It was 
found that radiolabeled cholesterol from perfusate of hepatic ACAT2 deficient mice was preferentially 
delivered to the proximal small intestine of wild type mice. 192 
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A similar phenomenon probably occurs in mice deficient in the rate-limiting enzyme for BS synthesis 
(cholesterol 7α-hydroxylase, Cyp7a1). Cyp7a1 null mice have reduced BS synthesis and excretion and 
a smaller intestinal BS pool, which is associated with a major impairment in cholesterol absorption. 
Compared to wildtype mice, they have the same dietary intake and biliary cholesterol level. Nevertheless, 
fecal neutral sterol excretion greatly exceeds the sum of total dietary and estimated biliary cholesterol 
input to the intestine in these mice. 193
Our lab contributed to the evidence by quantification of in vivo cholesterol fluxes from plasma and bile 
to feces by stable isotope methodology. 191 In these experiments, differentially stable isotope labeled 
cholesterol was administered to mice intravenously and orally to determine cholesterol absorption and 
label distribution over time in blood, bile and feces. In addition, cholesterol synthesis was measured 
by MIDA of blood, bile and fecal samples collected over time during administration of stable isotope 
labeled cholesterol precursor in drinking water. 191 
6.2.2 Transport of cholesterol from blood to feces
The transport of cholesterol from the blood compartment to the enterocyte and the subsequent 
excretion of cholesterol is probably facilitated by transport proteins. Sr-b1, being expressed on both 
the apical and basolateral side of enterocytes, was considered a possible candidate. However TICE was 
shown to be upregulated, rather than downregulated, in Sr-b1 knockout mice. 194 TICE was not altered by 
the absence of either Npc1l1 or Ldlr. 192,195 The relation between TICE and cholesterol efflux via Abcg5/g8 
is somewhat puzzling 135,185 Compared with wildtype mice, TICE was decreased in Abcg5 knockout mice 
during LXR agonist treatment and plant sterol/stanol consumption. 135,191. Strikingly however, TICE was 
not decreased by deletion of Abcg8 in mice. 187 
By gene expression analyses, so far no apical or basolateral transporters have been identified that 
regulate TICE. 8 At present it is unclear which lipoproteins are involved in donating the cholesterol to 
the TICE pathway and how it is targeted to the enterocytes. TICE does not seem to be mediated by HDL 
particles, based on unchanged fecal cholesterol excretion in mice deficient in HDL (Abca1 knockout 
mice). 65 Some evidence points to VLDL as a possible candidate origin for cholesterol involved in TICE. 192
Mice with liver specific depletion of Acat2 showed normal HDL levels, but increased delivery of liver-
derived cholesterol to the lumen of the proximal small intestine as well as increased fecal cholesterol 
excretion. 65,192 Alternatively, TICE may not be facilitated via lipoprotein transport, but for example via 
increased delivery of erythrocyte cholesterol to the intestinal lumen. Additional research is required to 
identify key players in the pathway.
6.2.3 Stimulation of TICE
It is currently unclear whether or not ezetimibe, via inhibition of cholesterol absorption, could stimulate 
TICE. One study suggested pharmacological activation of TICE with ezetimibe. 196 However, this was not 





TICE can be stimulated with pharmaceuticals such as nuclear receptor agonists of LXR 189,191 and 
peroxisome proliferator-activated receptor delta (PPARδ). 195 A high fat (low cholesterol) diet also induces 
TICE. 194,197 
Dietary plant sterols were shown to inhibit cholesterol absorption in mice. Brufau et al. recently found 
that dietary plant sterols/ stanols dose dependently induce fecal neutral sterol excretion, without 
affecting biliary cholesterol secretion. These data provide new insight into the cholesterol lowering 
mechanism of action of plant sterols/ stanols. 135 
A recent study showed that mice with acute biliary diversion are able to secrete labeled cholesterol 
derived from intraperitoneally injected cholesterol-loaded macrophages to the intestinal lumen. 198 
This study adds to the evidence that TICE may be quantitatively more important than hepatobiliary 
cholesterol secretion in the elimination of cholesterol via fecal excretion (RCT).
6.2.4 TICE in humans?
Although the available evidence suggests that TICE may be present in humans 199,200, it is at present 
unclear if TICE is present under healthy conditions and whether it can be stimulated pharmacologically 
or, preferentially, by dietary means. It has been estimated that TICE may contribute to one-third of fecal 
excretion in humans. 187 The possibility of TICE has never been tested in models for predicting plasma 
cholesterol. In the future measurement of body cholesterol kinetics by stable isotope studies in humans 
may provide new insight into the excretion and regulation of plasma cholesterol, and the dietary and 
therapeutic strategies to decrease hypercholesterolemia and associated cardiovascular disease in man.
Scope of this thesis
The specific aim of the research described in this thesis was to determine the effect of manipulation 
of intestinal function (by dietary, pharmacological and genetic intervention) on lipid homeostasis, 
in particular cholesterol excretion. We hypothesized that acceleration of intestinal transit time could 
induce fecal lipid excretion. This could be desirable in case of hypercholesterolemia. On the other hand, 
many children nowadays suffer from constipation and are treated with oral laxatives. Administration of 
these laxatives could negatively impact on their intestinal absorbtive function and lead to fecal lipid loss. 
In chapter 2, we describe the effect of acceleration of intestinal transit on absorption of dietary fat 
and cholesterol. In chapter 3, we studied the effect of accelerated intestinal transit on BS homeostasis 
and intestinal microbiota. Changes in the composition of dietary fat have been shown to alter fecal fat 
excretion. For example, lowering the ratio of polyunsaturated to saturated fatty acids (P/S ratio) was 
shown to induce fecal fat excretion.In chapter 4, we studied the effect of two high fat diets with different 
P/S ratios on cholesterol homeostasis. We used stable isotope methodologies to determine cholesterol 
absorption, synthesis and we modified the method previously used 191 to determine the origin of fecal 
sterols. Bsep-/- mice were previously shown to display defective biliary BS secretion. However, this was by 
far not as prominent as in their human couterparts. 15 In chapter 5, we studied the effect of absence of 
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